Fagron

FAGR · Euronext Brussels · EUR

22,50 €Variación respecto al cierre anterior: −0,44 %Variación absoluta: −0,10 €

Cierre · 2 de octubre de 2026

Perfil de la empresa

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Descripción disponible en inglés.

Datos societarios

Sector
Industria
Industria
Drug Manufacturers - Specialty & Generic
Sede
Venecoweg 20A, 9810, Nazareth
Empleados
4.880
Cotización
FAGR · Euronext Brussels
Divisa
EUR
ISIN
BE0003874915
Sitio web
fagron.com